PMID- 36573953
OWN - NLM
STAT- MEDLINE
DCOM- 20221229
LR  - 20230103
IS  - 0042-465X (Print)
IS  - 0042-465X (Linking)
VI  - 138
IP  - 6
DP  - 2022
TI  - [Efficacy and safety of a fixed combination drug Brinzolol Duo in the treatment 
      of patients with primary open-angle glaucoma].
PG  - 99-106
LID - 10.17116/oftalma202213806199 [doi]
AB  - PURPOSE: To evaluate the efficacy and safety of a new fixed combination of 
      brinzolamide and timolol in patients with stages I and II of primary open-angle 
      glaucoma (POAG). MATERIAL AND METHODS: Study patients were divided into 2 groups. 
      The patients of the first group were prescribed Brinzolol Duo, the second group 
      received an original drug Azarga. Regimen for both drugs was 1 drop 2 times per 
      day for 84 days. The study included 7 monitoring visits: visit 0 (screening - 124 
      patients), visit 1 (randomization and treatment initiation - 120 patients), 
      visits 2-4 (therapy), visit 5 (end of therapy - 117 patients), visit 6 
      (follow-up, study completion). RESULTS: Out of 120 patients included in the 
      study, 117 subjects had completed all study procedures. It was shown that both 
      compared drugs significantly reduce intraocular pressure (IOP). After 3 months, 
      46.5% of patients in the Brinzolol Duo group and 46.9% of patients in the Azarga 
      group had IOP lowered by more than 30% compared to baseline, with IOP amounting 
      to </=18 mm Hg in 36.6% and 30.2% of patients, respectively. Hypotensive efficacy 
      and safety of the drugs were comparable between the groups (p>0.05). The drugs 
      were well tolerated, all adverse events (AEs) were mild or moderate in severity. 
      CONCLUSION: The new drug Brinzolol Duo (brinzolamide + timolol) significantly 
      reduces IOP in POAG patients with efficacy comparable to Azarga.
FAU - Loskutov, I A
AU  - Loskutov IA
AUID- ORCID: 0000-0003-0057-3338
AD  - Moscow Regional Research and Clinical Institute, Moscow, Russia.
FAU - Kolotilina, N E
AU  - Kolotilina NE
AUID- ORCID: 0000-0002-0730-5881
AD  - Medical Center for Diagnostics and Prevention, Yaroslavl, Russia.
FAU - Bleskina, M Yu
AU  - Bleskina MY
AUID- ORCID: 0000-0003-4938-3201
AD  - Clinical Center No. 7, Moscow, Russia.
FAU - Lisitsyn, A B
AU  - Lisitsyn AB
AUID- ORCID: 0000-0002-5146-7140
AD  - Clinical Hospital No. 2, Yaroslavl, Russia.
FAU - Poromov, A A
AU  - Poromov AA
AUID- ORCID: 0000-0002-2004-3935
AD  - Peoples' Friendship University of Russia, Moscow, Russia.
AD  - I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Effektivnost' i bezopasnost' primeneniya novoi fiksirovannoi kombinatsii 
      Brinzolol Duo pri lechenii pervichnoi otkrytougol'noi glaukomy.
PL  - Russia (Federation)
TA  - Vestn Oftalmol
JT  - Vestnik oftalmologii
JID - 0415216
RN  - 817W3C6175 (Timolol)
RN  - 9451Z89515 (brinzolamide)
RN  - 0 (Drug Combinations)
RN  - 0 (Antihypertensive Agents)
SB  - IM
MH  - Humans
MH  - Timolol/adverse effects
MH  - *Glaucoma, Open-Angle/diagnosis/drug therapy/chemically induced
MH  - *Ocular Hypertension/drug therapy
MH  - Intraocular Pressure
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Antihypertensive Agents/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - brinzolamide
OT  - ocular hypertension
OT  - primary open-angle glaucoma
OT  - timolol
EDAT- 2022/12/28 06:00
MHDA- 2022/12/30 06:00
CRDT- 2022/12/27 10:57
PHST- 2022/12/27 10:57 [entrez]
PHST- 2022/12/28 06:00 [pubmed]
PHST- 2022/12/30 06:00 [medline]
AID - 10.17116/oftalma202213806199 [doi]
PST - ppublish
SO  - Vestn Oftalmol. 2022;138(6):99-106. doi: 10.17116/oftalma202213806199.